Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Sun Yat-sen University

Status and phase

Unknown

Phase 2

Conditions

Breast Cancer

Vinorelbine

Breast Diseases

Pyrotinib

HER2-positive Breast Cancer

Treatments

Drug: Pyrotinib plus Vinorelbine

Drug: Pyrotinib 400mg + Vinorelbine

Drug: Pyrotinib 320mg + Vinorelbine

Study type

Interventional

Funder types

Other

Identifiers

NCT04605575

MA-BC-II-002

Details and patient eligibility

About

The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer.

The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of pyrotinib and vinorelbine in patients with advanced solid tumors. In the second part of the study, we will explore the safety and efficacy of Pyrotinib + vinorelbine in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination.

Enrollment

208 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed invasive breast cancer
HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent. Patients who have previously used pertuzumab will be allowed.
Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria

History of treatment with pyrotinib
Prior treatment with lapatinib or neratinib
History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma
History of receiving any anti-cancer drug/biologic or investigational treatment within 28 days prior to randomization except hormone therapy
Recovery of treatment-related toxicity consistent with other eligibility criteria
History of radiation therapy within 28 days of randomization
Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
History of myocardial infarction or unstable angina
Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
Pregnancy or lactation
Current known active infection with human immunodeficiency virus (HIV) or hepatitis C virus
Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis